Epilepsies, Partial Clinical Trial
— NNAISOfficial title:
Novel Network Analysis of Intracranial Stereoelectroencephalography
Verified date | November 2021 |
Source | Great Ormond Street Hospital for Children NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Epilepsy is a disorder of the brain which is associated with disabling seizures and affects 100,000 people under 25. Many children with epilepsy also have a learning disability or problems with development. Although better outcomes occur in children who are successfully treated early for their epilepsy, 25% continue to have seizures despite best medical treatment. One potential treatment is a neurosurgical operation to remove parts of the brain that generate seizures. A proportion of these children have electrodes inserted into their brains as part of their clinical assessment, termed stereoelectroencephalography (SEEG), to help localise these regions. Subsequent surgery is not always successful - up to 40% of children will have ongoing seizures 5 years after surgery. The purpose of this study is to assess the utility of specially designed SEEG electrodes which can measure signals from single brain cells. These electrodes record the same clinical information as normal SEEG electrodes and are implanted in the same way, but can give the research team extra information at the same time. The investigators aim to assess whether studying the changes in the firing of individual cells, both during and between seizures, improves our ability to localise seizures and therefore improve outcomes following surgery. As part of this research project, the investigators will not be doing anything that is not already part of the normal investigation and treatment for these children. Children will be recruited to the study during routine outpatient clinic visits. Surgical planning and execution will not be affected. The electrodes are CE licensed for clinical use and do not alter the risks of the operation. Following the period of monitoring, the care of these children would not be altered in any way. The investigators aim to recruit 30 patients over 3 years. In addition to dissemination via scientific publications and presentations, the findings will be shared with participants and the public.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | April 2022 |
Est. primary completion date | April 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 18 Years |
Eligibility | Inclusion Criteria: - Undergoing SEEG recording as part of the investigation of their epilepsy at Great Ormond Street Hospital for Children - Aged 3-18 - Participant/parents provide informed consent for inclusion Exclusion Criteria: - Lack of informed consent |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Great Ormond Street Hospital NHS Foundation Trust | London |
Lead Sponsor | Collaborator |
---|---|
Great Ormond Street Hospital for Children NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Analyse single unit behaviour in different brain regions. | We will assess the abnormalities in single neuron firing behaviour both during and between seizures in children undergoing stereoelectroencephalogaphy (SEEG) as part of work-up for epilepsy surgery.
The statistical analysis will include measures of timing coding and population coding of these single units and the investigators will assess these properties in time periods both during and between seizures to assess whether neurons in the seizure onset zone behave differently to those outside the seizure onset zone: Timing coding is evaluated using a generalized linear modeling (GLM) approach. An output of the GLM is called a post-spike filter (PSF), which models the propensity for the same neuron to fire again over the course of the subsequent 0.7 seconds. Population coding is also evaluated using a GLM by calculating coupling filters (the amount of up and down regulation of all other recorded neurons given that an individual neuron has just fired). |
Recording will continue for a period of 5-10 days, as determined by the clinical team. We will therefore use the data collected over the entire recording period for analysis. | |
Primary | Correlate firing activity of single units to the clinically defined seizure onset zone (SOZ) | Currently, the seizure onset zone (SOZ) is determined by visual analysis of the SEEG recordings at the end of the monitoring period.
We aim to compare the differences in single unit behaviour (as defined above) between and during seizures in neurons inside and outside this clinically defined SOZ to assess if there is a unique behaviour to these neurons. |
Recording will continue for a period of 5-10 days, as determined by the clinical team. We will therefore use the data collected over the entire recording period for analysis. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00524030 -
Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures
|
Phase 3 | |
Completed |
NCT00143143 -
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
|
Phase 3 | |
Completed |
NCT00771927 -
Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
|
N/A | |
Completed |
NCT00236873 -
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
|
Phase 2 | |
Completed |
NCT01745952 -
Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS)
|
N/A | |
Completed |
NCT00772603 -
Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures
|
Phase 3 | |
Completed |
NCT00280696 -
A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures
|
Phase 3 | |
Completed |
NCT00643136 -
A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures
|
Phase 3 | |
Completed |
NCT00230698 -
A Study of the Effectiveness and Safety of Topiramate Monotherapy in Patients With Recently Diagnosed Partial-Onset Seizure
|
Phase 3 | |
Completed |
NCT00072813 -
MRI in Autosomal Dominant Partial Epilepsy With Auditory Features
|
N/A | |
Enrolling by invitation |
NCT04309812 -
Transcranial Direct Current to Treat Epilepsy at Home
|
Early Phase 1 | |
Withdrawn |
NCT00422110 -
A Study to Evaluate the Efficacy and Safety of Seletracetam in Adult Patients With Refractory Partial Onset Seizures
|
Phase 2/Phase 3 | |
Completed |
NCT00620555 -
A Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
|
Phase 3 | |
Completed |
NCT00448916 -
Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures
|
Phase 3 | |
Completed |
NCT00210522 -
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
|
Phase 2 | |
Completed |
NCT00236886 -
Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients
|
Phase 3 | |
Completed |
NCT00236860 -
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
|
Phase 2 | |
Active, not recruiting |
NCT03689114 -
Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)
|
Phase 4 | |
Completed |
NCT01098162 -
Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug
|
N/A | |
Completed |
NCT05273398 -
Effects of Diazepam on RNS Detections
|
Phase 4 |